Caricamento...
Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors
CTLA-4 is an immune checkpoint expressed on active anticancer T cells. When it combines with its ligand B7 on dendritic cells, it inhibits the activity of the T cells. The Bromo- and Extra-Terminal (BET) protein family includes proteins that regulate the expression of key oncogenes and antiapoptotic...
Salvato in:
| Pubblicato in: | Proc Natl Acad Sci U S A |
|---|---|
| Autori principali: | , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
National Academy of Sciences
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6003484/ https://ncbi.nlm.nih.gov/pubmed/29735668 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1721559115 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|